Development of TLR9 agonists for cancer therapy
J. Clin. Invest. Arthur M. Krieg, et al. 117:1184 doi:10.1172/JCI31414 [Go to this article.]

Figure 1
Backbones of native and modified DNA. PS ODN differ from native phosphodiester (PO) DNA ODN only in the substitution of a sulfur for one of the nonbridging oxygen atoms. This change improves the in vivo stability of the ODN from a half-life of a few minutes to about two days for the PS ODN.